{"pmid":32462501,"title":"The Allplex 2019-nCoV (Seegene) assay: which performances are for SARS-CoV-2 infection diagnosis?","text":["The Allplex 2019-nCoV (Seegene) assay: which performances are for SARS-CoV-2 infection diagnosis?","Several commercial assays for SARS-CoV-2 RT-PCR are available but few of them were assessed. We evaluate the Allplex 2019-nCoV (Seegene) assay using 41 nasopharyngeal samples. The rates of agreement were 92.7% and 100% with the GeneFinder COVID-19 plus (Elitech) and the diagnosis of the infectious disease specialist respectively. Four samples display a Ct < 22.0 for the E and RdRp genes while the N gene was not detected, suggesting a variability of the viral sequence. There was no cross-reactivity with other respiratory viruses. The Allplex 2019-nCoV appears as a reliable method, but additional evaluations using more samples are needed. RT-PCR assays should probably include at least 2 viral targets.","Eur J Clin Microbiol Infect Dis","Farfour, Eric","Lesprit, Philippe","Visseaux, Benoit","Pascreau, Tiffany","Jolly, Emilie","Houhou, Nadira","Mazaux, Laurence","Asso-Bonnet, Marianne","Vasse, Marc","32462501"],"abstract":["Several commercial assays for SARS-CoV-2 RT-PCR are available but few of them were assessed. We evaluate the Allplex 2019-nCoV (Seegene) assay using 41 nasopharyngeal samples. The rates of agreement were 92.7% and 100% with the GeneFinder COVID-19 plus (Elitech) and the diagnosis of the infectious disease specialist respectively. Four samples display a Ct < 22.0 for the E and RdRp genes while the N gene was not detected, suggesting a variability of the viral sequence. There was no cross-reactivity with other respiratory viruses. The Allplex 2019-nCoV appears as a reliable method, but additional evaluations using more samples are needed. RT-PCR assays should probably include at least 2 viral targets."],"journal":"Eur J Clin Microbiol Infect Dis","authors":["Farfour, Eric","Lesprit, Philippe","Visseaux, Benoit","Pascreau, Tiffany","Jolly, Emilie","Houhou, Nadira","Mazaux, Laurence","Asso-Bonnet, Marianne","Vasse, Marc"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462501","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s10096-020-03930-8","keywords":["allplex 2019-ncov (seegene)","covid-19","nasopharyngeal swab","rt-pcr","sars-cov-2","sensitivity"],"topics":["Diagnosis"],"weight":1,"_version_":1668079521185660928,"score":9.490897,"similar":[{"pmid":32361322,"title":"Interpret with caution: An evaluation of the commercial AusDiagnostics versus in-house developed assays for the detection of SARS-CoV-2 virus.","text":["Interpret with caution: An evaluation of the commercial AusDiagnostics versus in-house developed assays for the detection of SARS-CoV-2 virus.","INTRODUCTION: There is limited data on the analytical performance of commercial nucleic acid tests (NATs) for laboratory confirmation of COVID-19 infection. METHODS: Nasopharyngeal, combined nose and throat swabs, nasopharyngeal aspirates and sputum was collected from persons with suspected SARS-CoV-2 infection, serial dilutions of SARS-CoV-2 viral cultures and synthetic positive controls (gBlocks, Integrated DNA Technologies) were tested using i) AusDiagnostics assay (AusDiagnostics Pty Ltd); ii) in-house developed assays targeting the E and RdRp genes; iii) multiplex PCR assay targeting endemic respiratory viruses. Discrepant SARS-CoV-2 results were resolved by testing the N, ORF1b, ORF1ab and M genes. RESULTS: Of 52 clinical samples collected from 50 persons tested, respiratory viruses were detected in 22 samples (42 %), including SARS CoV-2 (n=5), rhinovirus (n=7), enterovirus (n=5), influenza B (n=4), hMPV (n=5), influenza A (n=2), PIV-2 (n=1), RSV (n=2), CoV-NL63 (n=1) and CoV-229E (n=1). SARS-CoV-2 was detected in four additional samples by the AusDiagnostics assay. Using the in-house assays as the \"gold standard\", the sensitivity, specificity, positive and negative predictive values of the AusDiagnostics assay was 100 %, 92.16 %, 55.56 % and 100 % respectively. The Ct values of the real-time in-house-developed PCR assay targeting the E gene was significantly lower than the corresponding RdRp gene assay when applied to clinical samples, viral culture and positive controls (mean 21.75 vs 28.1, p=0.0031). CONCLUSIONS: The AusDiagnostics assay is not specific for the detection SARS-CoV-2. Any positive results should be confirmed using another NAT or sequencing. The case definition used to investigate persons with suspected COVID-19 infection is not specific.","J Clin Virol","Rahman, H","Carter, I","Basile, K","Donovan, L","Kumar, S","Tran, T","Ko, D","Alderson, S","Sivaruban, T","Eden, J-S","Rockett, R","O'Sullivan, M V","Sintchenko, V","Chen, S C-A","Maddocks, S","Dwyer, D E","Kok, J","32361322"],"abstract":["INTRODUCTION: There is limited data on the analytical performance of commercial nucleic acid tests (NATs) for laboratory confirmation of COVID-19 infection. METHODS: Nasopharyngeal, combined nose and throat swabs, nasopharyngeal aspirates and sputum was collected from persons with suspected SARS-CoV-2 infection, serial dilutions of SARS-CoV-2 viral cultures and synthetic positive controls (gBlocks, Integrated DNA Technologies) were tested using i) AusDiagnostics assay (AusDiagnostics Pty Ltd); ii) in-house developed assays targeting the E and RdRp genes; iii) multiplex PCR assay targeting endemic respiratory viruses. Discrepant SARS-CoV-2 results were resolved by testing the N, ORF1b, ORF1ab and M genes. RESULTS: Of 52 clinical samples collected from 50 persons tested, respiratory viruses were detected in 22 samples (42 %), including SARS CoV-2 (n=5), rhinovirus (n=7), enterovirus (n=5), influenza B (n=4), hMPV (n=5), influenza A (n=2), PIV-2 (n=1), RSV (n=2), CoV-NL63 (n=1) and CoV-229E (n=1). SARS-CoV-2 was detected in four additional samples by the AusDiagnostics assay. Using the in-house assays as the \"gold standard\", the sensitivity, specificity, positive and negative predictive values of the AusDiagnostics assay was 100 %, 92.16 %, 55.56 % and 100 % respectively. The Ct values of the real-time in-house-developed PCR assay targeting the E gene was significantly lower than the corresponding RdRp gene assay when applied to clinical samples, viral culture and positive controls (mean 21.75 vs 28.1, p=0.0031). CONCLUSIONS: The AusDiagnostics assay is not specific for the detection SARS-CoV-2. Any positive results should be confirmed using another NAT or sequencing. The case definition used to investigate persons with suspected COVID-19 infection is not specific."],"journal":"J Clin Virol","authors":["Rahman, H","Carter, I","Basile, K","Donovan, L","Kumar, S","Tran, T","Ko, D","Alderson, S","Sivaruban, T","Eden, J-S","Rockett, R","O'Sullivan, M V","Sintchenko, V","Chen, S C-A","Maddocks, S","Dwyer, D E","Kok, J"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361322","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jcv.2020.104374","keywords":["covid-19","nat","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495895207936,"score":260.14203},{"pmid":32416600,"title":"Comparison of seven commercial RT-PCR diagnostic kits for COVID-19.","text":["Comparison of seven commercial RT-PCR diagnostic kits for COVID-19.","The final months of 2019 witnessed the emergence of a novel coronavirus in the human population. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has since spread across the globe and is posing a major burden on society. Measures taken to reduce its spread critically depend on timely and accurate identification of virus-infected individuals by the most sensitive and specific method available, i.e. real-time reverse transcriptase PCR (RT-PCR). Many commercial kits have recently become available, but their performance has not yet been independently assessed. The aim of this study was to compare basic analytical and clinical performance of selected RT-PCR kits from seven different manufacturers (Altona Diagnostics, BGI, CerTest Biotec, KH Medical, PrimerDesign, R-Biopharm AG, and Seegene). We used serial dilutions of viral RNA to establish PCR efficiency and estimate the 95 % limit of detection (LOD95). Furthermore, we ran a panel of SARS-CoV-2-positive clinical samples (n = 13) for a preliminary evaluation of clinical sensitivity. Finally, we used clinical samples positive for non-coronavirus respiratory viral infections (n = 6) and a panel of RNA from related human coronaviruses to evaluate assay specificity. PCR efficiency was >/=96 % for all assays and the estimated LOD95 varied within a 6-fold range. Using clinical samples, we observed some variations in detection rate between kits. Importantly, none of the assays showed cross-reactivity with other respiratory (corona)viruses, except as expected for the SARS-CoV-1 E-gene. We conclude that all RT-PCR kits assessed in this study may be used for routine diagnostics of COVID-19 in patients by experienced molecular diagnostic laboratories.","J Clin Virol","van Kasteren, Puck B","van der Veer, Bas","van den Brink, Sharon","Wijsman, Lisa","de Jonge, Jorgen","van den Brandt, Annemarie","Molenkamp, Richard","Reusken, Chantal B E M","Meijer, Adam","32416600"],"abstract":["The final months of 2019 witnessed the emergence of a novel coronavirus in the human population. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has since spread across the globe and is posing a major burden on society. Measures taken to reduce its spread critically depend on timely and accurate identification of virus-infected individuals by the most sensitive and specific method available, i.e. real-time reverse transcriptase PCR (RT-PCR). Many commercial kits have recently become available, but their performance has not yet been independently assessed. The aim of this study was to compare basic analytical and clinical performance of selected RT-PCR kits from seven different manufacturers (Altona Diagnostics, BGI, CerTest Biotec, KH Medical, PrimerDesign, R-Biopharm AG, and Seegene). We used serial dilutions of viral RNA to establish PCR efficiency and estimate the 95 % limit of detection (LOD95). Furthermore, we ran a panel of SARS-CoV-2-positive clinical samples (n = 13) for a preliminary evaluation of clinical sensitivity. Finally, we used clinical samples positive for non-coronavirus respiratory viral infections (n = 6) and a panel of RNA from related human coronaviruses to evaluate assay specificity. PCR efficiency was >/=96 % for all assays and the estimated LOD95 varied within a 6-fold range. Using clinical samples, we observed some variations in detection rate between kits. Importantly, none of the assays showed cross-reactivity with other respiratory (corona)viruses, except as expected for the SARS-CoV-1 E-gene. We conclude that all RT-PCR kits assessed in this study may be used for routine diagnostics of COVID-19 in patients by experienced molecular diagnostic laboratories."],"journal":"J Clin Virol","authors":["van Kasteren, Puck B","van der Veer, Bas","van den Brink, Sharon","Wijsman, Lisa","de Jonge, Jorgen","van den Brandt, Annemarie","Molenkamp, Richard","Reusken, Chantal B E M","Meijer, Adam"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416600","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104412","keywords":["covid-19","coronavirus","in vitro diagnostics","rt-pcr","sars-cov-2","ncov-2019"],"topics":["Diagnosis"],"weight":1,"_version_":1666991242700914688,"score":255.56621},{"pmid":32388471,"title":"Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting.","text":["Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting.","BACKGROUND: The ongoing SARS-CoV-2 pandemic presents a unique challenge for diagnostic laboratories around the world. Automation of workflows in molecular diagnostics is instrumental for coping with the large number of tests ordered by clinicians, as well as providing fast-tracked rapid testing for highly urgent cases. In this study we evaluated a SARS-CoV-2 LDT for the NeuMoDx 96 system, a fully automated device performing extraction and real-time PCR. METHODS: A publicly available SARS-CoV-2 RT-PCR assay was adapted for the automated system. Analytical performance was evaluated using in-vitro transcribed RNA and clinical performance was compared to the cobas 6800-based reference assay within the lab. RESULTS: The Envelope (E) Gene-LDT displayed good analytical performance with an LoD of 95.55 cp/mL and no false positives during evaluation of cross-reactivity. A total of 176 patient samples were tested with both the E-Gene-LDT and the reference assay. Positive and negative agreement were 100 % and 99.2 % respectively. Invalid-rate was 6.3 %. CONCLUSION: The E-Gene-LDT showed analytical and clinical performance comparable to the cobas6800-based reference assay. Due to its random-access workflow concept and rapid time-to-result of about 80 min, the system is very well suited for providing fast-tracked SARS-CoV-2 diagnostics for urgent clinical samples in the hospital setting.","J Clin Virol","Norz, Dominik","Fischer, Nicole","Schultze, Alexander","Kluge, Stefan","Mayer-Runge, Ulrich","Aepfelbacher, Martin","Pfefferle, Susanne","Lutgehetmann, Marc","32388471"],"abstract":["BACKGROUND: The ongoing SARS-CoV-2 pandemic presents a unique challenge for diagnostic laboratories around the world. Automation of workflows in molecular diagnostics is instrumental for coping with the large number of tests ordered by clinicians, as well as providing fast-tracked rapid testing for highly urgent cases. In this study we evaluated a SARS-CoV-2 LDT for the NeuMoDx 96 system, a fully automated device performing extraction and real-time PCR. METHODS: A publicly available SARS-CoV-2 RT-PCR assay was adapted for the automated system. Analytical performance was evaluated using in-vitro transcribed RNA and clinical performance was compared to the cobas 6800-based reference assay within the lab. RESULTS: The Envelope (E) Gene-LDT displayed good analytical performance with an LoD of 95.55 cp/mL and no false positives during evaluation of cross-reactivity. A total of 176 patient samples were tested with both the E-Gene-LDT and the reference assay. Positive and negative agreement were 100 % and 99.2 % respectively. Invalid-rate was 6.3 %. CONCLUSION: The E-Gene-LDT showed analytical and clinical performance comparable to the cobas6800-based reference assay. Due to its random-access workflow concept and rapid time-to-result of about 80 min, the system is very well suited for providing fast-tracked SARS-CoV-2 diagnostics for urgent clinical samples in the hospital setting."],"journal":"J Clin Virol","authors":["Norz, Dominik","Fischer, Nicole","Schultze, Alexander","Kluge, Stefan","Mayer-Runge, Ulrich","Aepfelbacher, Martin","Pfefferle, Susanne","Lutgehetmann, Marc"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388471","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104390","keywords":["covid-19","neumodx","pcr","rapid testing","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666428892759457792,"score":225.53873},{"pmid":32501535,"title":"Identification of nsp1 gene as the target of SARS-CoV-2 real-time RT-PCR using nanopore whole genome sequencing.","text":["Identification of nsp1 gene as the target of SARS-CoV-2 real-time RT-PCR using nanopore whole genome sequencing.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the COVID-19 pandemic. Accurate detection of SARS-CoV-2 using molecular assays is critical for patient management and the control of the COVID-19 pandemic. However, there is an increasing number of SARS-CoV-2 viruses with mutations at the primer or probe binding sites, and these mutations may affect the sensitivity of currently available real-time reverse transcription-polymerase chain reaction (RT-PCR) assays targeting the N, E, and ORF1a/b genes. Using sequence-independent single-primer amplification (SISPA) and nanopore whole-genome sequencing, we have found that the nsp1 gene, located at the 5' end of the SARS-CoV-2 genome, was highly expressed in the nasopharyngeal or saliva specimens of 9 COVID-19 patients of different clinical severity. Based on this finding, we have developed a novel nsp1 real-time RT-PCR assay. The primers and probes are highly specific for SARS-CoV-2. Validation with 101 clinical specimens showed that our nsp1 RT-PCR assay has a sensitivity of 93.1% (95% confidence interval, 86.2-97.2%), which was similar to those of N and E gene RT-PCR assays. The diagnostic specificity was 100% (95% CI, 92.9-100%). The addition of nsp1 for multi-target detection of SARS-CoV-2 can avoid false negative results due to mutations at the primers/probes binding sites of currently available RT-PCR assays. This article is protected by copyright. All rights reserved.","J Med Virol","Chan, Wan-Mui","Ip, Jonathan Daniel","Chu, Allen Wing-Ho","Yip, Cyril Chik-Yan","Lo, Lap-Sum","Chan, Kwok-Hung","Ng, Anthony Chin-Ki","Poon, Rosana Wing-Shan","To, Wing-Kin","Tsang, Owen Tak-Yin","Leung, Wai-Shing","Kwan, Mike Yat-Wah","Chua, Gilbert T","Chung, Tom Wai-Hin","Hung, Ivan Fan-Ngai","Kok, Kin-Hang","Cheng, Vincent Chi-Chung","Chan, Jasper Fuk-Woo","Yuen, Kwok-Yung","To, Kelvin Kai-Wang","32501535"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the COVID-19 pandemic. Accurate detection of SARS-CoV-2 using molecular assays is critical for patient management and the control of the COVID-19 pandemic. However, there is an increasing number of SARS-CoV-2 viruses with mutations at the primer or probe binding sites, and these mutations may affect the sensitivity of currently available real-time reverse transcription-polymerase chain reaction (RT-PCR) assays targeting the N, E, and ORF1a/b genes. Using sequence-independent single-primer amplification (SISPA) and nanopore whole-genome sequencing, we have found that the nsp1 gene, located at the 5' end of the SARS-CoV-2 genome, was highly expressed in the nasopharyngeal or saliva specimens of 9 COVID-19 patients of different clinical severity. Based on this finding, we have developed a novel nsp1 real-time RT-PCR assay. The primers and probes are highly specific for SARS-CoV-2. Validation with 101 clinical specimens showed that our nsp1 RT-PCR assay has a sensitivity of 93.1% (95% confidence interval, 86.2-97.2%), which was similar to those of N and E gene RT-PCR assays. The diagnostic specificity was 100% (95% CI, 92.9-100%). The addition of nsp1 for multi-target detection of SARS-CoV-2 can avoid false negative results due to mutations at the primers/probes binding sites of currently available RT-PCR assays. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chan, Wan-Mui","Ip, Jonathan Daniel","Chu, Allen Wing-Ho","Yip, Cyril Chik-Yan","Lo, Lap-Sum","Chan, Kwok-Hung","Ng, Anthony Chin-Ki","Poon, Rosana Wing-Shan","To, Wing-Kin","Tsang, Owen Tak-Yin","Leung, Wai-Shing","Kwan, Mike Yat-Wah","Chua, Gilbert T","Chung, Tom Wai-Hin","Hung, Ivan Fan-Ngai","Kok, Kin-Hang","Cheng, Vincent Chi-Chung","Chan, Jasper Fuk-Woo","Yuen, Kwok-Yung","To, Kelvin Kai-Wang"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501535","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26140","keywords":["covid-19","rt-pcr","sars-cov-2","diagnosis","nanopore sequencing","nsp1"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1668890966407249920,"score":218.68004},{"pmid":32276116,"pmcid":"PMC7144850","title":"Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay.","text":["Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay.","OBJECTIVE: To evaluate a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and compare it with RT-PCR. METHODS: We designed primers specific to the orf1ab and S genes of SARS-CoV-2. Total viral RNA was extracted using the QIAamp Viral RNA Mini Kit. We optimized the RT-LAMP assay, and evaluated it for its sensitivity and specificity of detection using real-time turbidity monitoring and visual observation. RESULTS: The primer sets orf1ab-4 and S-123 amplified the genes in the shortest times, the mean (+/-SD) times were 18 +/- 1.32 min and 20 +/- 1.80 min, respectively, and 63 degrees C was the optimum reaction temperature. The sensitivities were 2 x 10(1) copies and 2 x 10(2) copies per reaction with primer sets orf1ab-4 and S-123, respectively. This assay showed no cross-reactivity with 60 other respiratory pathogens. To describe the availability of this method in clinical diagnosis, we collected 130 specimens from patients with clinically suspected SARS-CoV-2 infection. Among them, 58 were confirmed to be positive and 72 were negative by RT-LAMP. The sensitivity was 100% (95% CI 92.3%-100%), specificity 100% (95% CI 93.7%-100%). This assay detected SARS-CoV-2 in a mean (+/-SD) time of 26.28 +/- 4.48 min and the results can be identified with visual observation. CONCLUSION: These results demonstrate that we developed a rapid, simple, specific and sensitive RT-LAMP assay for SARS-CoV-2 detection among clinical samples. It will be a powerful tool for SARS-CoV-2 identification, and for monitoring suspected patients, close contacts and high-risk groups.","Clin Microbiol Infect","Yan, C","Cui, J","Huang, L","Du, B","Chen, L","Xue, G","Li, S","Zhang, W","Zhao, L","Sun, Y","Yao, H","Li, N","Zhao, H","Feng, Y","Liu, S","Zhang, Q","Liu, D","Yuan, J","32276116"],"abstract":["OBJECTIVE: To evaluate a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and compare it with RT-PCR. METHODS: We designed primers specific to the orf1ab and S genes of SARS-CoV-2. Total viral RNA was extracted using the QIAamp Viral RNA Mini Kit. We optimized the RT-LAMP assay, and evaluated it for its sensitivity and specificity of detection using real-time turbidity monitoring and visual observation. RESULTS: The primer sets orf1ab-4 and S-123 amplified the genes in the shortest times, the mean (+/-SD) times were 18 +/- 1.32 min and 20 +/- 1.80 min, respectively, and 63 degrees C was the optimum reaction temperature. The sensitivities were 2 x 10(1) copies and 2 x 10(2) copies per reaction with primer sets orf1ab-4 and S-123, respectively. This assay showed no cross-reactivity with 60 other respiratory pathogens. To describe the availability of this method in clinical diagnosis, we collected 130 specimens from patients with clinically suspected SARS-CoV-2 infection. Among them, 58 were confirmed to be positive and 72 were negative by RT-LAMP. The sensitivity was 100% (95% CI 92.3%-100%), specificity 100% (95% CI 93.7%-100%). This assay detected SARS-CoV-2 in a mean (+/-SD) time of 26.28 +/- 4.48 min and the results can be identified with visual observation. CONCLUSION: These results demonstrate that we developed a rapid, simple, specific and sensitive RT-LAMP assay for SARS-CoV-2 detection among clinical samples. It will be a powerful tool for SARS-CoV-2 identification, and for monitoring suspected patients, close contacts and high-risk groups."],"journal":"Clin Microbiol Infect","authors":["Yan, C","Cui, J","Huang, L","Du, B","Chen, L","Xue, G","Li, S","Zhang, W","Zhao, L","Sun, Y","Yao, H","Li, N","Zhao, H","Feng, Y","Liu, S","Zhang, Q","Liu, D","Yuan, J"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32276116","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.cmi.2020.04.001","keywords":["covid-19","detection","rt-lamp","sars-cov-2","visual"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491727118337,"score":211.28084}]}